PMEF
RYTM icon

Point72 Middle East FZE’s Rhythm Pharmaceuticals RYTM Stock Holding History

Point72 Middle East FZE’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-31,181
Closed -$715K – 1830
2023
Q3 		$715K Buy
+31,181
New +$698K 0.02% 687
2023
Q2 		– Sell
-10,339
Closed -$184K – 2011
2023
Q1 		$184K Buy
+10,339
New +$260K 0.01% 963

Other funds holding RYTM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Middle East FZE's RYTM Position: Q4 2023 in Review

Point72 Middle East FZE sold out of Rhythm Pharmaceuticals (RYTM) in Q4 2023, closing a stake of 31,181 shares — an estimated $715K sold.

Point72 Middle East FZE first reported a position in RYTM in Q1 2023 and held it in 2 quarters. The position peaked at $715K in Q3 2023. 168 funds tracked by Wall St. Rank hold RYTM as of Q4 2023.

  • Point72 Middle East FZE reported no remaining Rhythm Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 31,181 Rhythm Pharmaceuticals shares in Q4 2023, an estimated $715K.
  • Point72 Middle East FZE first reported a position in Rhythm Pharmaceuticals in Q1 2023 and held it in 2 quarters.
  • Point72 Middle East FZE's Rhythm Pharmaceuticals position peaked at $715K in Q3 2023.
  • 168 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q4 2023.

Based on Point72 Middle East FZE's 13F filing for Q4 2023, filed 14 Feb 2024.